Our examination across multiple cancers identified that uterine cancers harbored the most frequent genomic and transcriptional up-regulation of the γ-actin gene, ACTG1, and the myosin light chain kinase gene, MYLK2. Up to 20% of samples with gains were observed across each subtype including UMEC, USC, UEC, and UCS with limited mutations or deletions. The gene discussed is MYLK2; the disease is uterine cancer.